News & Comment

Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.

Extremity injuries occur frequently during warfare. While traditionally treated in definitive clinics, the future battlefield is projected to be different in a variety of ways, and there will likely be a shift towards prolonged field care (PFC) for treating extremity traumas. PFC is defined as field medical care that is applied beyond “doctrinal planning time-lines” by a tactical medical practitioner in order to decrease patient mortality and morbidity. At present, there is an urgent need to develop biologically focused technologies for treating extremity injuries in the PFC setting. Herein, the case is made for why rapid advancements in PFC is critical to achieve optimal care for injured Service members in the future, and important design criteria for developing next-generation biologically focused technologies. Finally, a case example—i.e., Gustilo Type III fracture—is presented to illustrate how these biologically focused technologies could be utilized to treat an extremity injury within a PFC environment.